Upgrade of MRD in the first 2 years of maintenance (in patients with available samples for MRD analysis)
| . | At screening . | ||
|---|---|---|---|
| Overall series N = 332 . | RD n = 161 . | IRD n = 171 . | |
| MRD negative | 184 (55.4%) | 82 (50.9%) | 102 (59.6%) |
| At 1 y of maintenance | |||
| Overall series | RD | IRD | |
| N = 252 | n = 121 | n = 131 | |
| MRD negative | 192 (72.6%) | 85 (70.2%) | 98 (74.8%) |
| At 2 y of maintenance | |||
| Overall series | RD | IRD | |
| N = 226 | n = 110 | n = 116 | |
| MRD negative | 163 (72.1%) | 79 (71.8%) | 84 (72.4%) |
| Upgrade of MRD negative at 2 y of maintenance | |||
| Overall series | RD | IRD | |
| 16.7% | 20.9% | 12.8% | |
| . | At screening . | ||
|---|---|---|---|
| Overall series N = 332 . | RD n = 161 . | IRD n = 171 . | |
| MRD negative | 184 (55.4%) | 82 (50.9%) | 102 (59.6%) |
| At 1 y of maintenance | |||
| Overall series | RD | IRD | |
| N = 252 | n = 121 | n = 131 | |
| MRD negative | 192 (72.6%) | 85 (70.2%) | 98 (74.8%) |
| At 2 y of maintenance | |||
| Overall series | RD | IRD | |
| N = 226 | n = 110 | n = 116 | |
| MRD negative | 163 (72.1%) | 79 (71.8%) | 84 (72.4%) |
| Upgrade of MRD negative at 2 y of maintenance | |||
| Overall series | RD | IRD | |
| 16.7% | 20.9% | 12.8% | |